Is LVCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
PM vs Fair Ratio
Share Price vs Fair Value
What is the Fair Price of LVCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LVCE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LVCE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LVCE?
Other financial metrics that can be useful for relative valuation.
|What is LVCE's n/a Ratio?
Price to Sales Ratio vs Peers
How does LVCE's PS Ratio compare to its peers?
ETST Earth Science Tech
TFFP TFF Pharmaceuticals
FLHL.F Filament Health
Price-To-Sales vs Peers: LVCE is good value based on its Price-To-Sales Ratio (10.2x) compared to the peer average (12x).
Price to Earnings Ratio vs Industry
How does LVCE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: LVCE is expensive based on its Price-To-Sales Ratio (10.2x) compared to the US Pharmaceuticals industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is LVCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio
|Fair PS Ratio
PM vs Fair Ratio: Insufficient data to calculate LVCE's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.